Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Exclusion Criteria

• •Have received following treatment before this study: a. Anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials.
• •History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years;
• •Have serious concurrent illness including, but not limited to uncontrolled congestive heart failure(NYHA classification grade III or IV), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure \>21.3 Kpa or diastolic blood pressure \>13.3 Kpa);
• •Have ongoing or active serious infection;
• •Have uncontrolled diabetes mellitus;
• •Psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol;
• •Active autoimmune diseases require long-term use of steroids or received allotransplantation
• •Other serious illness considered not suitable for this study by investigators.